ICML 2017 | BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
Christian Buske, MD of University Hospital Ulm, Ulm, Germany talks about the Phase III trial comparing BGB-3111 and ibrutinib in Waldenström’s macroglobulinemia (NCT03053440). The gold standard for treatment in Waldenström’s macroglobulinemia is ibrutinib, which is a BTK inhibitor approved for relapsed patients and in first-line for patients who are not eligible for immunochemotherapy. BGB-3111 is more selective than ibrutinib and therefore thought to be more effective. Preliminary data from a Phase I trial shows that patients treated with BGB-3111 achieve deep remissions and based on this, the Phase III trial was initiated. Prof. Buske explains that we need more data on BGB-3111 before we can assess its impact on clinical practice.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.
